This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jan 7, 2026
•
10 min read
🧬 Amgen to acquire Dark Blue Therapeutics for up to $840M to expand protein-degrading cancer pipeline, Arrowhead Pharma's ARO-INHBE doubles tirzepatide weight loss in type 2 diabetes patients in Ph1/Ph2a trial, Pfizer + Cartography Biosciences partner on tumor-selective antigen discovery - $65M upfront w/ $850M total potential, GSK's Exdensur (depemokimab) wins Japan approval for severe asthma and chronic rhinosinusitis with nasal polyps, Eli Lilly + Nimbus Therapeutics partner on preclinical oral obesity drug - $55M upfront + $1.3B biobucks, Bright Minds Biosciences' BMB-101 shows positive Ph2 results for drug-resistant absence seizures and developmental epilepsies, Mediar Therapeutics raises $76M Series B for clinical trials of fibrosis drugs
Jan 6, 2026
8 min read
🧬 Novo Nordisk launches oral Wegovy in US at $149 monthly out-of-pocket price - shares rise 2.6%, Moderna files for approval of mRNA-1010 seasonal influenza vaccine for adults aged 50 and older, Aktis Oncology aims for $209M IPO, developing miniprotein radiopharmaceuticals for cancer, Servier + Insilico Medicine partner on AI-driven oncology drug discovery in $32M upfront & $888M total deal, Incyte's Monjuvi (tafasitamab) shows Ph3 success in first-line diffuse large B-cell lymphoma - FDA filing planned, Neumora Therapeutics reports positive Ph1b results for NMRA-511 vasopressin 1a receptor antagonist in Alzheimer's disease agitation, Daiichi Sankyo plans $1.9B global Enhertu manufacturing investments across Japan, U.S., Germany, China
Jan 5, 2026
15 min read
🧬 Insilico Medicine’s long-awaited IPO hits the Hong Kong Stock Exchange - raises $296M for AI-driven drug discovery platform, BioMarin Pharmaceutical to acquire Amicus Therapeutics for $4.8 billion in all-cash deal, Sanofi to acquire Dynavax Technologies for $2.2B to gain hepatitis B vaccine Heplisav-B, Roche's Lunsumio (mosunetuzumab) subcutaneous formulation wins FDA approval for relapsed or refractory follicular lymphoma, Aktis Oncology files IPO for their radiopharmaceutical miniprotein radioconjugates for cancer treatment, Shionogi acquires Mitsubishi Tanabe Pharma's ALS drug Radicava for $2.5 billion, AbbVie + Suzhou Zelgen Biopharmaceuticals partner on trispecific DLL3 asset ZG006 - $100M upfront & $1.2B total w/biobucks, Boehringer Ingelheim's Jascayd wins FDA approval for progressive pulmonary fibrosis targeting phosphodiesterase 4B
Dec 19, 2025
9 min read
🧬 Novo Nordisk files CagriSema (cagrilintide/semaglutide) for FDA approval targeting amylin-GLP-1 pathways in obesity, Athira Pharma + Sermonix Pharmaceuticals partner on breast cancer drug lasofoxifene for $34.9M equity + $100M milestones, Insilico Medicine aims for $292M IPO on the Hong Kong Stock Exchange, AI-powered drug discovery and development platform, Novartis builds largest global R&D hub outside Switzerland in India with 9,000 employees, Orum Therapeutics raises $100M funding, degrader-antibody conjugates for cancer treatment, Syremis Therapeutics launches with $165M Series A to develop M1/M4 muscarinic drug rivaling BMS’s Cobenfy for schizophrenia
Dec 18, 2025
🧬 Addition Therapeutics emerges from stealth with $100M to develop novel gene therapies for chronic + rare diseases, Merck & Co.'s Keytruda (pembrolizumab) plus Padcev hits Ph3 endpoints in perioperative muscle-invasive bladder cancer treatment, Boehringer Ingelheim + Galux partner on AI-driven precision protein design research using GaluxDesign platform, Alnylam Pharmaceuticals invests $250M to expand RNAi manufacturing facility using new enzymatic ligation technology, Cascade Pharmaceuticals raises $46M Series B for phase III trials and pipeline development, BMS + Harbour BioMed collaborate on multi-specific antibodies - $90M upfront + $1.035B milestones, Johnson & Johnson's Rybrevant Faspro (amivantamab) receives FDA approval as first subcutaneous EGFR-targeted non-small cell lung cancer therapy
Dec 17, 2025
🧬 Genentech + Caris Life Sciences collaborate on AI-driven cancer target discovery with $25M upfront + $1.1B milestones, Link Cell Therapies debuts with $60M series A for logic-gated CAR-T platform, Allink Biotherapeutics raises $47M Series A extension to advance ADC clinical programs, Ambros Therapeutics launches with $125M Series A to advance Italian non-opioid pain drug neridronate, Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for $315M, Fosun Pharma acquires 53% stake in Green Valley Pharmaceuticals for $200M - reviving Alzheimer's drug GV-971, GSK's Exdensur (depemokimab) wins FDA approval for severe eosinophilic asthma treatment following Ph3 trials, Pfizer plans 15 obesity trials next year to replace $17 billion patent cliff revenue loss
Dec 16, 2025
🧬 Chai Discovery raises $130M Series B for AI-powered drug design suite development, XOMA Royalty acquires Generation Bio for $4.29 per share plus contingent value rights, Novo Nordisk launches Ozempic in India - pricing lowest dose at $24 weekly for diabetes market, Link Cell Therapies raises $60M Series A to develop next-gen CAR-T therapies, Kyverna Therapeutics' miv-cel CAR-T therapy meets Ph2 endpoints for stiff person syndrome, Adaptive Biotechnologies + Pfizer partner on TCR platform for rheumatoid arthritis in up to $890M biobucks deal, Sanofi in-licenses Adel Therapeutics Alzheimer's antibody ADEL-Y01 for $80M upfront and up to $1.04B total deal value, FDA approves AstraZeneca and Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki) for first-line HER2-positive metastatic breast cancer
Dec 15, 2025
🧬 William Blair predicts biotech sector will outperform 2021-24 bear markets in 2026 outlook, CIRM approves $160M funding for regenerative medicine research and clinical trials, Zealand Pharma seeks brain-targeting obesity treatment partners - explores shuttle technology collaborations, Tenaya Therapeutics raises $60M public offering to develop heart disease therapies, Sobi acquires Arthrosi Therapeutics for $950M upfront - adding gout treatment pozdeutinurad to pipeline, Anixa Biosciences' alpha-lactalbumin vaccine shows positive Ph1 results for triple-negative breast cancer prevention, Innovent Biologics' mazdutide (GLP-1/glucagon dual agonist) shows significant weight loss in Ph1b obesity trial in Chinese adolescents, FDA expands Johnson & Johnson's Akeega (abiraterone/niraparib) approval for BRCA2-mutated metastatic castration-sensitive prostate cancer
Dec 13, 2025
14 min read
How a $25M startup is solving gene therapy's $4 million payment problem
Dec 12, 2025
🧬 Zealand Pharma + OTR Therapeutics partner on metabolic disease therapeutics with $20M upfront + $2.5B biobucks, Amgen's Uplizna (inebilizumab) wins FDA approval for generalized myasthenia gravis targeting CD19-positive B cells, Xcell Biosciences + Culture Biosciences partner to advance cell therapy quality through AI and machine learning, Eli Lilly's retatrutide (triple hormone receptor agonist) achieves 26.6% weight loss in Ph3 obesity trial, Aukera Therapeutics emerges from stealth with CHF 4.5M ($5.63M) funding for neurological RAPTOR inhibitor development, Prolynx raises $70M Series A for longer-lasting obesity drugs with less frequent dosing, European legislators agree on major pharma policy overhaul reducing drug exclusivity periods + strengthening supply chains
Dec 11, 2025
🧬 FDA approves Fondazione Telethon's gene therapy for Wiskott-Aldrich syndrome - first gene therapy approved from a non-profit sponsor, Formation Bio + Lynk Pharmaceuticals partner on TYK2 inhibitor LNK01006 with $605M total deal value, InduPro Therapeutics + Sanofi partner on bispecific PD-1 agonist for autoimmune disorders with undisclosed equity investment, Roche's giredestrant (oral SERD) shows 30% risk reduction in Ph3 early estrogen receptor-positive breast cancer trial, PsiThera raises $47.5M Series A for AI-designed oral drugs for immune conditions, Great Point Partners acquires majority stake in Lenis Group - specialty pharmaceutical distributor in Central and Eastern Europe, FDA finalizes guidance on promotional materials for biologics and biosimilars requiring accurate + non-misleading advertising
Dec 10, 2025
🧬 Pfizer vaults another attempt towards an obesity pill by partnering with YaoPharma on Ph1 asset YP05002 - $150M upfront + $1.94B biobucks, Roche's Gazyvaro (obinutuzumab) wins EU approval for lupus nephritis treatment following Ph3 trial success, Cellular Origins raises $40M Series A for cell therapy manufacturing automation platform, Eli Lilly selects Alabama for $6B API facility to produce weight-loss pill orforglipron, Bora Pharmaceuticals + Corealis Pharma form strategic alliance for end-to-end oral solid dose development and production, Sidera Bio raises $109M Series A, developing obesity GLP-1/GIP/FGF21 triple agonist, BioNTech and Bristol Myers Squibb report positive Ph2 data for pumitamig in triple-negative breast cancer, Novartis' ianalumab hits Ph3 endpoints in immune thrombocytopenia
![The $4 Million Problem [Guest Post]](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/publication/thumbnail/5a180b8a-b34c-48db-a2ed-64c17f43d4d9/landscape_Screenshot_2025-11-27_at_10.21.52_PM.png)
